[HTML][HTML] A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
MN Levine, C Gu, HA Liebman, CP Escalante… - Journal of Thrombosis …, 2012 - Elsevier
Background: Cancer patients receiving chemotherapy are at increased risk for thrombosis.
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring.
Objectives: A pilot study was conducted to evaluate whether apixaban would be well
tolerated and acceptable in cancer patients receiving chemotherapy. Patients/Methods:
Subjects receiving either first‐line or second‐line chemotherapy for advanced or metastatic
lung, breast, gastrointestinal, bladder, ovarian or prostate cancers, cancer of unknown …
Apixaban, a factor Xa inhibitor, is oral and does not require laboratory monitoring.
Objectives: A pilot study was conducted to evaluate whether apixaban would be well
tolerated and acceptable in cancer patients receiving chemotherapy. Patients/Methods:
Subjects receiving either first‐line or second‐line chemotherapy for advanced or metastatic
lung, breast, gastrointestinal, bladder, ovarian or prostate cancers, cancer of unknown …
以上显示的是最相近的搜索结果。 查看全部搜索结果